Schizophrenia remains a challenging disease to treat effectively with current antipsychotic
medications due to their limited efficacy across the entire spectrum of core symptoms as well …

Pre-clinical models, postmortem and neuroimaging studies all support a role for muscarinic
receptors in the molecular pathology of schizophrenia. From these data it was proposed that …

Objective: The authors used longitudinal biobank data with up to 25 years of follow-up on
over 2,600 clozapine users to derive reliable estimates of the real-world burden of clozapine …

Introduction Clozapine (CLZ) is the superior drug in treatment of schizophrenia. Serum
concentration of CLZ is associated with clinical response and dose-dependents side effects …

Background Valproic acid (VPA) is frequently used with clozapine (CLZ) as mood stabilizer
and/or seizure prophylaxis. Valproic acid is known to reduce N-desmethylclozapine (N …

Clozapine is the only antipsychotic approved for treating treatment-resistant schizophrenia
(TRS), characterized by persistent positive symptoms despite adequate antipsychotic …

Objective Clozapine is presently the sole antipsychotic with an indication for treatment‐
resistant Schizophrenia, but is associated with significant weight gain and other metabolic …

Introduction: Observational studies highlight associations of common diseases with
individual schizophrenia symptoms. However, it is unclear whether these diseases are …

Background: Extant research on cognitive functioning in treatment-resistant schizophrenia
(TRS) is limited and of poor quality. Cognitive impairments in patients with schizophrenia …

Schizophrenia affects approximately 24 million people worldwide and clozapine is the most
effective antipsychotic drug. Nevertheless, its use in therapy is limited due to adverse effects …